STEPHEN YENZEN LAI to Antibodies, Monoclonal
This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Antibodies, Monoclonal.
Connection Strength
0.027
-
Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol. 2011 Nov; 22(11):2482-2488.
Score: 0.009
-
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010 Dec 20; 28(36):5294-300.
Score: 0.009
-
Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy. In Vivo. 2010 Jan-Feb; 24(1):1-8.
Score: 0.009